U

United Therapeutics Corp
D

UTHR

371.50
USD
3.46
(0.94%)
مغلق
حجم التداول
14,313
الربح لكل سهم
28
العائد الربحي
-
P/E
16
حجم السوق
16,585,438,809
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ALKS
    0.140
    (0.47%)
    30.220 USD
    I
    INVA
    -0.210
    (-1.12%)
    18.540 USD
    LLY
    LLY
    11.37
    (1.53%)
    753.86 USD
    MRK
    MRK
    -0.560
    (-0.58%)
    95.670 USD
    PFE
    PFE
    -0.621
    (-2.33%)
    26.015 USD
    P
    PTCT
    -0.150
    (-0.33%)
    45.100 USD
    VRTX
    VRTX
    0.08
    (0.02%)
    428.09 USD
    المزيد
الأخبار
المقالات

العنوان: United Therapeutics Corp

القطاع: Healthcare
الصناعة: Biotechnology
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus onthe prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.